IL216804A0 - Methods for treating chronic kidney disease - Google Patents

Methods for treating chronic kidney disease

Info

Publication number
IL216804A0
IL216804A0 IL216804A IL21680411A IL216804A0 IL 216804 A0 IL216804 A0 IL 216804A0 IL 216804 A IL216804 A IL 216804A IL 21680411 A IL21680411 A IL 21680411A IL 216804 A0 IL216804 A0 IL 216804A0
Authority
IL
Israel
Prior art keywords
methods
kidney disease
chronic kidney
treating chronic
treating
Prior art date
Application number
IL216804A
Other languages
English (en)
Original Assignee
Quark Pharmaceuticals Inc
Us Of America Represented By The United States Dept Of Veteran S Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Pharmaceuticals Inc, Us Of America Represented By The United States Dept Of Veteran S Affairs filed Critical Quark Pharmaceuticals Inc
Publication of IL216804A0 publication Critical patent/IL216804A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL216804A 2009-06-08 2011-12-06 Methods for treating chronic kidney disease IL216804A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18493709P 2009-06-08 2009-06-08
US23538109P 2009-08-20 2009-08-20
PCT/US2010/037565 WO2010144336A2 (en) 2009-06-08 2010-06-07 Methods for treating chronic kidney disease

Publications (1)

Publication Number Publication Date
IL216804A0 true IL216804A0 (en) 2012-02-29

Family

ID=43309421

Family Applications (1)

Application Number Title Priority Date Filing Date
IL216804A IL216804A0 (en) 2009-06-08 2011-12-06 Methods for treating chronic kidney disease

Country Status (8)

Country Link
US (2) US8637482B2 (https=)
EP (2) EP2440214A4 (https=)
JP (1) JP2012529430A (https=)
CN (1) CN102458418B (https=)
CA (1) CA2763537A1 (https=)
DK (1) DK3276004T3 (https=)
IL (1) IL216804A0 (https=)
WO (1) WO2010144336A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103562387A (zh) 2011-03-03 2014-02-05 夸克医药公司 Toll样受体途径的寡核苷酸调剂
US9796979B2 (en) 2011-03-03 2017-10-24 Quark Pharmaceuticals Inc. Oligonucleotide modulators of the toll-like receptor pathway
US9631170B2 (en) 2011-10-06 2017-04-25 University Of Wyoming Genetically inducible hydrogen peroxide resistance and production
DK2895608T3 (en) 2012-09-12 2019-01-21 Quark Pharmaceuticals Inc DOUBLE-STRENGTHED OIGONUCLEOTIDE MOLECULES FOR P53 AND PROCEDURES FOR USING IT
US9932578B2 (en) 2012-09-12 2018-04-03 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to P53 and methods of use thereof
US9546364B2 (en) 2013-03-15 2017-01-17 Carnegie Mellon University Synthetic lariat RNA for RNA interference
CN104073517A (zh) * 2013-03-28 2014-10-01 卫生部北京医院 p66Shc重组腺病毒载体及构建和应用
CA3184836A1 (en) * 2013-05-14 2014-11-20 Metabolon, Inc. Biomarkers related to kidney function and methods using the same
LT3149172T (lt) 2014-05-29 2018-09-10 Quark Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti organų išeminės reperfuzijos pažeidimo prevencijai
GB201413081D0 (en) * 2014-07-23 2014-09-03 Univ Birmingham Markers for AF
ES2627997B1 (es) * 2015-09-18 2018-05-21 Fundación Instituto De Investigación Sanitaria Fundación Jiménez Díaz Uso de una composición farmacéutica para la fabricación de un medicamento para el tratamiento y/o la prevención del daño renal agudo
EP4442200A3 (en) * 2016-04-01 2024-12-04 Cardiac Pacemakers, Inc. Multi-disease patient management
WO2018027149A1 (en) * 2016-08-04 2018-02-08 University Of Miami Methods of treating alport syndrome
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
US11771113B2 (en) 2017-05-31 2023-10-03 Mars, Incorporated Methods of diagnosing and treating chronic kidney disease
CN116726173B (zh) * 2022-03-03 2025-09-23 浙江大学 Trpm2抑制剂的用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US20050032067A1 (en) 2002-11-05 2005-02-10 Prakash Thazha P. Non-phosphorous-linked oligomeric compounds and their use in gene modulation
US20050042647A1 (en) 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
CZ296576B6 (cs) 1999-02-12 2006-04-12 Sankyo Company Limited Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
CN1612930A (zh) 2001-11-21 2005-05-04 三菱化学株式会社 抑制基因表达的方法
AU2003260370B2 (en) 2002-08-05 2008-05-22 Silence Therapeutics Gmbh Further novel forms of interfering RNA molecules
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
CA2519860C (en) 2003-03-21 2018-01-16 Santaris Pharma A/S Short interfering rna (sirna) analogues
AU2005288522B2 (en) * 2004-09-28 2012-06-28 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
NL2000439C2 (nl) * 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
EP1989307B1 (en) 2006-02-08 2012-08-08 Quark Pharmaceuticals, Inc. NOVEL TANDEM siRNAS
US7910566B2 (en) * 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
CA2665365A1 (en) * 2006-10-05 2008-04-10 Rhode Island Hospital Compositions and methods for detecting and treating renal injury and inflammation
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US7872119B2 (en) * 2007-02-26 2011-01-18 Quark Pharmaceuticals, Inc. Inhibitors of RTP801 and their use in disease treatment
US20100292301A1 (en) 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
WO2009001359A2 (en) 2007-06-27 2008-12-31 Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of pro-apoptotic genes
WO2009032915A2 (en) * 2007-09-06 2009-03-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Arrays, kits and cancer characterization methods
AU2008306455C1 (en) * 2007-10-03 2014-04-17 Quark Pharmaceuticals, Inc. Novel siRNA structures
US20090226547A1 (en) 2008-03-05 2009-09-10 Gilbard Jeffrey P Dietary Supplement For Eye Health
US20110028531A1 (en) * 2008-03-20 2011-02-03 Elena Feinstein Novel sirna compounds for inhibiting rtp801

Also Published As

Publication number Publication date
CN102458418B (zh) 2015-09-16
EP2440214A2 (en) 2012-04-18
JP2012529430A (ja) 2012-11-22
CA2763537A1 (en) 2010-12-16
DK3276004T3 (da) 2020-04-06
EP3276004A3 (en) 2018-03-14
US20120141378A1 (en) 2012-06-07
EP2440214A4 (en) 2013-07-31
US8637482B2 (en) 2014-01-28
US20140140922A1 (en) 2014-05-22
WO2010144336A2 (en) 2010-12-16
WO2010144336A3 (en) 2011-02-03
EP3276004B1 (en) 2020-03-18
CN102458418A (zh) 2012-05-16
EP3276004A2 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
IL216804A0 (en) Methods for treating chronic kidney disease
IL257418A (en) Methods for treating addiction
PL2480255T3 (pl) Terapia przewlekłych zakażeń jelitowych
IL233017A0 (en) Methods for treating spinal cord pathologies
PT2440545T (pt) Compostos úteis para tratar cancro
AP2011005956A0 (en) Methods of treatment for solid tumors.
GB0822068D0 (en) Methods for virus design
GB2475018B (en) Water treatment methods
ZA201204845B (en) Agents for treating disease
IL231680B (en) Activated carbon fiber for treating or preventing kidney disease or dialysis complications
EP2300608A4 (en) METHODS OF TREATING SOLID TUMORS
EP2621497A4 (en) ASSOCIATION TREATMENT FOR ROSE ACNE
EP2144888A4 (en) METHODS OF TREATING CANCER
GB201013898D0 (en) Well treatment
EP2410846A4 (en) GLYCOLIPIDES AS TREATMENT OF DISEASES
IL213919A0 (en) Methods to treat cancer
EP2240192A4 (en) TREATMENT OF DERMATOLOGICAL SUFFERING
IL194373A0 (en) Methods for treating kidney disorders
IL207906A0 (en) Treatment for ocular-related disorders
ZA201201894B (en) Pharmaceutical combination for treating tumor
GB0809046D0 (en) Cancer treatment
PL2928461T3 (pl) Leczenie przewlekłej choroby nerek
GB0920940D0 (en) Agent for treating disease
GB0920942D0 (en) Agent for treating disease
GB0920933D0 (en) Agent for treating disease